Axsome Therapeutics Inc (OQ:AXSM)

Apr 17, 2024 09:00 pm ET
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Axsome Therapeutics, Inc. (NASDAQ: AXSM) on behalf of long-term stockholders following a class action complaint that was...
Apr 15, 2024 07:00 am ET
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced presentations highlighting its innovative psychiatry and...
Apr 12, 2024 02:30 am ET
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Axsome Therapeutics, Inc. (NASDAQ: AXSM) on behalf of long-term stockholders following a class action complaint that was...
Apr 03, 2024 09:00 pm ET
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Axsome Therapeutics, Inc. (NASDAQ: AXSM) on behalf of long-term stockholders following a class action complaint that was...
Apr 01, 2024 07:00 am ET
Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, announced the initiation of the ENGAGE Phase 3 trial of solriamfetol, an...
Mar 25, 2024 09:00 pm ET
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Axsome Therapeutics, Inc. (NASDAQ: AXSM) on behalf of long-term stockholders following a class action complaint that was...
Mar 25, 2024 09:31 am ET
Thinking about trading options or stock in Arm Holdings, UiPath, Dell Technologies, Digital World Acquisition, or Axsome Therapeutics?
NEW YORK, March 25, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ARM, PATH, DELL, DWAC, and AXSM.
Mar 25, 2024 07:00 am ET
Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced topline results from the CRESCENDO (Characterizing Patient...
Mar 25, 2024 06:30 am ET
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that AXS-12 (reboxetine), a highly selective and potent...
Mar 19, 2024 07:00 am ET
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced the first patient has been dosed in the PARADIGM Phase 3...
Mar 05, 2024 07:00 am ET
Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive...
Feb 27, 2024 07:00 am ET
Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive...
Feb 20, 2024 07:00 am ET
Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced reported financial results for the fourth quarter and...
Jan 23, 2024 07:00 am ET
Axsome Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced it will report its financial results for the fourth...
Jan 04, 2024 07:00 am ET
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced preliminary net product revenue for the fourth quarter and...
Dec 11, 2023 07:00 am ET
Axsome Therapeutics Presents New Data and Post-Hoc Analyses of Auvelity® in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2023 Annual Meeting
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced new data that treatment with Auvelity®...
Dec 07, 2023 07:00 am ET
Axsome Therapeutics Hosts Solriamfetol Virtual Investor Event with Expert Thought Leaders Today
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, is hosting a virtual investor event and conference call today from 8 a.m....
Dec 05, 2023 02:00 pm ET
Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Axsome Therapeutics, Inc. (AXSM) Investors of Class Action and Encourages Shareholders to Contact the Firm
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Axsome Therapeutics, Inc. (“Axsome” or “the Company”) (NASDAQ: AXSM) and certain of...
Nov 29, 2023 04:48 pm ET
Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Axsome Therapeutics, Inc. (AXSM) Investors of Class Action and Encourages Shareholders to Contact the Firm
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Axsome Therapeutics, Inc. (“Axsome” or “the Company”) (NASDAQ: AXSM) and certain of...
Nov 28, 2023 06:51 pm ET
Axsome Therapeutics, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; December 7, 2023 deadline.
The Portnoy Law Firm advises Axsome Therapeutics, Inc. ("Axsome" or "the Company") (NASDAQ:AXSM) investors that a lawsuit filed on behalf of investors that purchased Axsome securities between May 10, 2021 and April 22, 2022, inclusive (the “Class...
Nov 27, 2023 07:36 pm ET
AXSM DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action – AXSM
WHY: Rosen Law Firm, a global investor rights law firm, reminds investors of the common stock of Axsome Therapeutics, Inc. (“Axsome”) (NASDAQ: AXSM) of the reopening of the lead plaintiff appointment process in a class action lawsuit against...
Nov 24, 2023 04:10 pm ET
AXSM FINAL DEADLINE ALERT: ROSEN, A LEADING LAW FIRM, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action – AXSM
WHY: Rosen Law Firm, a global investor rights law firm, reminds investors of the common stock of Axsome Therapeutics, Inc. (“Axsome”) (NASDAQ: AXSM) of the reopening of the lead plaintiff appointment process in a class action lawsuit against...
Nov 22, 2023 07:00 am ET
Axsome Therapeutics to Host Solriamfetol Virtual Investor Event on December 7
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that it will host a virtual event on December 7 from 8...
Nov 21, 2023 07:00 am ET
Axsome Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive...
Nov 17, 2023 08:26 pm ET
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action – AXSM
WHY: Rosen Law Firm, a global investor rights law firm, announces the reopening of the lead plaintiff appointment process in a class action lawsuit against Axsome Therapeutics, Inc. (“Axsome” or the “Company”) (NASDAQ: AXSM) and certain of...
Nov 16, 2023 08:28 pm ET
Rosen Law Firm Announces the Reopening of the Lead Plaintiff Appointment Process in a Class Action Against Axsome Therapeutics, Inc. and Certain Officers – AXSM
Rosen Law Firm announces the reopening of the lead plaintiff appointment process in a class action lawsuit against Axsome Therapeutics, Inc. (“Axsome” or the “Company”) (NASDAQ: AXSM) and certain of its officers. The Class Action, filed in the United States District Court for the Southern District of New York, and docketed under 22-cv-03925 (LGS), is proposed to be brought on behalf of a Class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Axsome common stock between May 10, 2021 and April 22, 2022, both dates inclusive (the “Class Period”), s
Nov 06, 2023 07:00 am ET
Axsome Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the third quarter ended September...
Nov 02, 2023 07:00 am ET
Axsome Therapeutics and the Global Alzheimer’s Disease Community Come Together in Raising Support for the Millions Affected by This Illness During Alzheimer’s Disease Awareness Month 2023
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced it is joining advocacy organizations around the world to...
Oct 31, 2023 07:00 am ET
Axsome Therapeutics to Present at Upcoming Investor Conferences
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive...
Oct 24, 2023 07:00 am ET
Axsome Therapeutics Presents Results of the ACCORD trial of AXS-05 in Alzheimer’s Disease Agitation at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Conference
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced a presentation of data from its ACCORD Phase 3 clinical...
Oct 11, 2023 07:00 am ET
Axsome Therapeutics Appoints Dr. Sue Mahony to its Board of Directors
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Susan Mahony, PhD, has been appointed to Axsome’s...
Oct 10, 2023 07:00 am ET
Axsome Therapeutics to Report Third Quarter 2023 Financial Results on November 6
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that it will report its financial results for the third...
Oct 02, 2023 07:00 am ET
Axsome Therapeutics Joins the National Alliance on Mental Illness and Others Advocating for the Importance of Mental Health on Mental Illness Awareness Week
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced it is joining patient advocacy organizations, including...
Sep 28, 2023 09:00 pm ET
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Axsome Therapeutics, Inc. (NASDAQ: AXSM) on behalf of long-term stockholders following a class action complaint that was filed against Axsome on May 13, 2022 with a Class Period from December 30, 2019 to April 22, 2022. Our investigation concerns whether the board of directors of Axsome have breached their fiduciary duties to the company.
Sep 21, 2023 07:00 am ET
Axsome Therapeutics Joins the Global Narcolepsy Community in Raising Awareness on World Narcolepsy Day
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced it is joining the global narcolepsy advocacy community,...
Sep 07, 2023 07:03 am ET
Axsome Therapeutics Highlights Commitment to Innovating Treatments for Mental Health Conditions with Presentations at Psych Congress 2023
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced presentations of data from its CNS portfolio at the 2023...
Sep 05, 2023 07:00 am ET
Axsome Therapeutics to Present at Three Upcoming Investor Conferences
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive...
Aug 07, 2023 07:00 am ET
Axsome Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the second quarter ended June 30,...
Jul 12, 2023 07:00 am ET
Axsome Therapeutics to Report Second Quarter 2023 Financial Results on August 7
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that it will report its financial results for the second...
Jul 07, 2023 07:00 am ET
Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that it has dosed the first patient in the FOCUS Phase 3...
Jun 30, 2023 04:02 pm ET
Axsome Therapeutics Announces Closing of Public Offering of $225 Million of Shares of Common Stock
Axsome Therapeutics, Inc. (NASDAQ: AXSM) (“Axsome” or the “Company”), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced the closing of its previously...
Jun 28, 2023 09:31 am ET
Thinking about trading options or stock in Microsoft, Amazon.com, Alphabet Inc, Overstock.com, or ?
NEW YORK, June 28, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MSFT, AMZN, GOOGL, OSTK, and AXSM.
Jun 28, 2023 09:28 am ET
Axsome Therapeutics Announces Pricing of Public Offering of $225 Million of Shares of Common Stock
Axsome Therapeutics, Inc. (NASDAQ: AXSM) (“Axsome” or the “Company”), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced the pricing of an underwritten...
Jun 27, 2023 08:24 pm ET
Axsome Therapeutics Announces Proposed Public Offering of Common Stock
Axsome Therapeutics, Inc. (NASDAQ: AXSM) (“Axsome” or the “Company”), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it intends to offer and sell shares of...
Jun 01, 2023 07:00 am ET
Axsome Therapeutics to Present New Sunosi® Data at SLEEP 2023
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced presentations on Sunosi® (solriamfetol) at SLEEP 2023, the...
May 31, 2023 11:20 am ET
Thinking about buying stock in Krystal Biotech, Axsome Therapeutics, 89bio, Scpharmaceuticals, or Decibel Therapeutics?
NEW YORK, May 31, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for KRYS, AXSM, ETNB, SCPH, and DBTX.
May 30, 2023 07:00 am ET
Axsome Therapeutics to Present Data and Post-Hoc Analyses on Auvelity® and Sunosi® at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced presentations on Auvelity® (dextromethorphan-bupropion),...
May 08, 2023 12:30 pm ET
Thinking about trading options or stock in Zscaler Inc, Sea Ltd, Axsome Therapeutics Inc, Alcoa Corp, or Matador Resources Co?
NEW YORK, May 8, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ZS, SE, AXSM, AA, and MTDR.
May 08, 2023 07:00 am ET
Axsome Therapeutics Reports First Quarter 2023 Financial Results and Corporate Update
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the first quarter ended March 31,...
May 03, 2023 07:00 am ET
Axsome Therapeutics to Present at the Bank of America Securities 2023 Healthcare Conference
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive...
May 01, 2023 07:00 am ET
Axsome Therapeutics Joins Mental Health America and the State of New York to Raise Awareness of Mental Health During May is Mental Health Month
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, is joining Mental Health America (MHA) and the State of New York to raise...
Apr 21, 2023 07:00 am ET
Axsome Therapeutics to Present Five Abstracts Including New Data from the Positive SHARP Study of SUNOSI® (solriamfetol) in Participants with Cognitive Impairment with Excessive Daytime Sleepiness in
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that it will be presenting five abstracts at the upcoming...
Apr 14, 2023 07:00 am ET
Axsome Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive...
Apr 13, 2023 07:00 am ET
Axsome Therapeutics to Report First Quarter 2023 Financial Results on May 8
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that it will report its financial results for the first...
Mar 14, 2023 09:30 am ET
SHAREHOLDER ALERT: Axsome Therapeutics, Inc. (AXSM) Officers and Directors Face Shareholder Investigation for Alleged Securities Law Violations
SAN FRANCISCO, March 14, 2023 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP is investigating potential derivative claims on behalf of shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM) relating to securities law violations and unlawful business practices.
Mar 01, 2023 07:00 am ET
Axsome Therapeutics to Present at Cowen’s 43rd Annual Health Care Conference
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive...
Feb 27, 2023 08:31 am ET
Thinking about trading options or stock in Tesla, Coinbase Global, Axsome Therapeutics, Chevron, or Walt Disney?
NEW YORK, Feb. 27, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TSLA, COIN, AXSM, CVX, and DIS.
Feb 27, 2023 07:00 am ET
Axsome Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the fourth quarter and full year...
Feb 22, 2023 07:00 am ET
Axsome Therapeutics Enters into License Agreement with Pharmanovia to Expand Commercialization and Further Develop Sunosi® (solriamfetol) in Europe
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that it has entered into an exclusive license agreement...
Feb 17, 2023 08:31 am ET
Thinking about trading options or stock in AutoNation, DoorDash, Axsome Therapeutics, NVIDIA, or Microsoft?
NEW YORK, Feb. 17, 2023 /PRNewswire/ --  InvestorsObserver issues critical PriceWatch Alerts for AN, DASH, AXSM, NVDA, and MSFT.
Feb 07, 2023 07:00 am ET
Axsome Therapeutics to Present at the SVB Securities Global Biopharma Conference
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive...
Jan 31, 2023 07:00 am ET
Axsome Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 27
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that it will report its financial results for the fourth...
Dec 07, 2022 07:00 am ET
Axsome Therapeutics Presents New Data from the EVOLVE Open-Label Trial Demonstrating Effects of AUVELITY® on Cognitive and Physical Functioning in Patients with Major Depressive Disorder at the Americ
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that treatment with AUVELITY® (dextromethorphan...
Nov 28, 2022 08:31 am ET
Thinking about trading options or stock in Axsome Therapeutics, Sarepta Therapeutics, Las Vegas Sands, Apple, or Microsoft?
NEW YORK, Nov. 28, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AXSM, SRPT, LVS, AAPL, and MSFT.
Nov 28, 2022 06:35 am ET
Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in the ACCORD Phase 3 Trial in Alzheimer’s Disease Agitation
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that AXS-05, a novel, oral, investigational NMDA receptor...
Nov 23, 2022 07:00 am ET
Axsome Therapeutics to Present at the 5th Annual Evercore ISI HealthCONx Conference
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive...
Nov 09, 2022 07:00 am ET
Axsome Therapeutics to Present at the Guggenheim 4th Annual Immunology and Neurology Conference
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive...
Nov 07, 2022 07:00 am ET
Axsome Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the third quarter ended September 30,...
Oct 27, 2022 07:00 am ET
Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive...
Oct 21, 2022 07:00 am ET
Axsome Therapeutics to Report Third Quarter 2022 Financial Results on November 7, 2022
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that it will report its financial results for the third...
Oct 20, 2022 07:00 am ET
Axsome Therapeutics Announces Availability of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that AUVELITY™ (dextromethorphan HBr-bupropion HCl) is now...
Oct 13, 2022 09:41 am ET
Thinking about trading options or stock in Axsome Therapeutics, Coca-Cola, Papa John's, Apple, or Twitter?
NEW YORK, Oct. 13, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AXSM, KO, PZZA, AAPL, and TWTR.
Oct 10, 2022 07:00 am ET
Axsome Therapeutics Voices its Commitment to Mental Health on World Mental Health Day 2022
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, is joining the World Health Organization’s (WHO) 2022 World Mental Health...
Oct 03, 2022 09:31 am ET
Thinking about buying stock in Protagonist Therapeutics, BP, Nio, Axsome Therapeutics, or Petroleo Brasileiro?
NEW YORK, Oct. 3, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PTGX, BP, NIO, AXSM, and PBR.
Oct 03, 2022 06:30 am ET
Axsome Therapeutics Announces Sunosi® (Solriamfetol) Meets Primary Endpoint Demonstrating Improvement in Cognitive Function in the SHARP Trial in Cognitively Impaired Patients with Excessive Daytime S
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, announced that Sunosi met the primary endpoint in the SHARP study and...
Sep 29, 2022 09:31 am ET
Thinking about trading options or stock in Alcoa, XPO Logistics, Axsome Therapeutics, Apple, or Biogen?
NEW YORK, Sept. 29, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AA, XPO, AXSM, AAPL, and BIIB.
Sep 29, 2022 07:28 am ET
Axsome Therapeutics Announces Plans to Resubmit AXS-07 NDA Based on Successful FDA Type A Meeting
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, announced that, following a Type A meeting with the U.S. Food and Drug...
Sep 21, 2022 07:00 am ET
Axsome Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive...
Sep 14, 2022 07:00 am ET
Axsome Therapeutics to Present at the Cowen 2nd Annual Novel Mechanisms in Neuropsychiatry Summit
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive...
Sep 08, 2022 07:00 am ET
Axsome Therapeutics Initiates ADVANCE-2 Phase 3 Trial of AXS-05 in Alzheimer’s Disease Agitation
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, announced that it has enrolled the first patient in the ADVANCE-2 trial of...
Sep 07, 2022 07:00 am ET
Axsome Therapeutics Announces Publication of Post-hoc Analysis of Sunosi® Effect on Excessive Daytime Sleepiness in Narcolepsy or Obstructive Sleep Apnea Patients with a History of Depression in the J
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced the publication of a post-hoc analysis comparing the...
Sep 06, 2022 07:00 am ET
Axsome Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive...
Sep 01, 2022 07:00 am ET
Axsome Therapeutics Initiates EMERGE Phase 3 Open-Label Trial of AXS-07 for the Acute Treatment of Migraine in Adults with a Prior Inadequate Response to an Oral CGRP Inhibitor
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, announced that it has enrolled the first patient in the EMERGE trial of...
Aug 26, 2022 10:50 pm ET
AXSOME THERAPEUTICS INVESTIGATION INITIATED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Axsome Therapeutics, Inc. - AXSM
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Axsome Therapeutics, Inc. (“Axsome” or the “Company”) (NasdaqGM: AXSM).
Aug 22, 2022 09:31 am ET
Thinking about buying stock in Greenbrook TMS, AMC Entertainment, Axsome Therapeutics, Bed Bath & Beyond, or Enovix Corp?
NEW YORK, Aug. 22, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GBNH, AMC, AXSM, BBBY, and ENVX.
Aug 19, 2022 08:30 am ET
Thinking about buying stock in Axsome Therapeutics, Foot Locker, Mind Medicine, Digital Media Solutions, or Provention Bio?
NEW YORK, Aug. 19, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AXSM, FL, MNMD, DMS, and PRVB.
Aug 19, 2022 06:45 am ET
Axsome Therapeutics Announces FDA Approval of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has...
Aug 12, 2022 10:50 pm ET
AXSOME THERAPEUTICS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Axsome Therapeutics, Inc. - AXSM
NEW ORLEANS, Aug. 12, 2022 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Axsome Therapeutics, Inc. ("Axsome" or the "Company") (NasdaqGM: AXSM).  
Aug 09, 2022 07:00 am ET
Axsome Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the second quarter ended June 30,...
Jul 30, 2022 07:00 pm ET
AXSOME THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Axsome Therapeutics, Inc. - AXSM
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Axsome Therapeutics, Inc. (“Axsome” or the “Company”) (NasdaqGM: AXSM).
Jul 28, 2022 07:00 am ET
Axsome Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that it will report its financial results for the second...
Jul 22, 2022 06:43 pm ET
Investigation Alert: Johnson Fistel, LLP Encourages Long-Term Investors to Contact the Firm; Should Management be Held Accountable for Investors’ Losses?
Axsome Therapeutics, Inc. (NASDAQ: AXSM)Johnson Fistel, LLP is investigating potential claims on behalf of Axsome Therapeutics, Inc. (NASDAQ: AXSM) against certain of its officers and directors. If you have continuously owned Axsome shares before...
Jul 12, 2022 10:50 am ET
FINAL DEADLINE ALERT: The Schall Law Firm Encourages Investors in Axsome Therapeutics, Inc. with Losses of $500,000 to Contact the Firm
LOS ANGELES , July 12, 2022 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Axsome Therapeutics, Inc. ("Axsome" or "the Company") (NASDAQ: AXSM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Jul 12, 2022 08:11 am ET
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Axsome Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Axsome Therapeutics, Inc. (“Axsome” or “the Company”) (NASDAQ:
Jul 12, 2022 05:45 am ET
AXSM ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of July 12, 2022 in the Class Action Filed on Behalf of Axsome Therapeutics, Inc. Shareholders
NEW YORK, July 12, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM) alleging that the Company violated federal securities laws.
Jul 11, 2022 04:22 pm ET
SHAREHOLDER ALERT FILING DEADLINE TODAY: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Axsome Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - AXSM
NEW YORK, July 11, 2022 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Axsome Therapeutics, Inc. ("Axsome" or the "Company") (NASDAQ: AXSM) and certain of its officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 22-cv-03925, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Axsome securities between December 30, 2019 and April 22, 2022, both dates inclusive (the "Class Period"), seeking to recover damage
Jul 11, 2022 12:00 pm ET
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Axsome Therapeutics, Inc. (AXSM)
The Law Offices of Frank R. Cruz reminds investors of the upcoming July 12, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Axsome Therapeutics, Inc. (“Axsome” or the “Company”) (NASDAQ:
Jul 11, 2022 10:45 am ET
DEADLINE ALERT for FHS, OSCR, UPST, and AXSM: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Jul 11, 2022 08:46 am ET
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Axsome Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Axsome Therapeutics, Inc. (“Axsome” or “the Company”) (NASDAQ:
Jul 11, 2022 05:45 am ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Axsome Investors of a Lead Plaintiff Deadline of July 12, 2022
NEW YORK, July 11, 2022 /PRNewswire/ -- Attention Axsome Therapeutics, Inc. ("Axsome") (NASDAQ: AXSM) shareholders:
Jul 10, 2022 05:15 pm ET
AXSM Final Deadline July 12: ROSEN, A TOP RANKED LAW FIRM, Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Tuesday Deadline in Securities Class Action – A
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Axsome Therapeutics, Inc. (NASDAQ: AXSM) between December 30, 2019 and April 22, 2022, inclusive (the “Class Period”), of the important July 12, 2022...
Jul 08, 2022 09:00 pm ET
AXSOME DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Axsome Therapeutics, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Axsome Therapeutics, Inc. (“Axsome” or the “Company”) (NASDAQ: AXSM) in the United States District Court for the Southern District of New York on behalf of all persons and entities who purchased or otherwise acquired Axsome securities between December 30, 2019 and April 22, 2022, both dates inclusive (the “Class Period”). Investors have until July 12, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Jul 08, 2022 01:03 pm ET
Axsome Therapeutics, Inc. Investors: Filing date July 12, 2022; Contact the Portnoy Law Firm to Recover Losses
The Portnoy Law Firm advises Axsome Therapeutics, Inc. (“Axsome” or the “Company”) (NASDAQ: AXSM) investors that a class action filed on behalf of investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email:...
Jul 06, 2022 01:00 pm ET
DEADLINE ALERT for FHS, OSCR, UPST, AXSM: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jul 06, 2022 01:30 am ET
AXSOME THERAPEUTICS, INC. (NASDAQ: AXSM) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit A
Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the...
Jul 05, 2022 11:45 am ET
DEADLINE ALERT for FHS, OSCR, UPST, and AXSM: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Jul 04, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against First High-School, Upstart, Oscar Health, and Axsome and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of First High-School Education Group Co., Ltd. (NYSE: FHS), Upstart Holdings, Inc....
Jul 02, 2022 12:00 pm ET
ROSEN, A LEADING LAW FIRM, Encourages Axsome Therapeutics, Inc. Investors with Losses Over $100K to Secure Counsel Before Important July 12 Deadline in Securities Class Action – AXSM
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Axsome Therapeutics, Inc. (NASDAQ: AXSM) between December 30, 2019 and April 22, 2022, inclusive (the “Class Period”), of the important July 12, 2022...
Jul 01, 2022 11:20 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Axsome Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – AXSM
Pomerantz LLP announces that a class action lawsuit has been filed against Axsome Therapeutics, Inc. (“Axsome” or the “Company”) (NASDAQ: AXSM) and certain of its officers.   The class action, filed in the United States District Court for the...
Jul 01, 2022 11:00 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Axsome Therapeutics, Inc. (AXSM)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming July 12, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Axsome Therapeutics, Inc. (“Axsome” or...
Jun 30, 2022 05:45 am ET
AXSM LAWSUIT ALERT: Levi & Korsinsky Notifies Axsome Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, June 30, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Axsome Therapeutics, Inc. ("Axsome" or the "Company") (NASDAQ: AXSM) of a class action securities lawsuit.
Jun 29, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against First High-School, Upstart, Oscar, and Axsome and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of First High-School Education Group Co., Ltd. (NYSE: FHS), Upstart Holdings, Inc....
Jun 29, 2022 05:56 pm ET
AXSOME THERAPEUTICS, INC. (NASDAQ: AXSM) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit A
Did you lose money on investments in Axsome Therapeutics? If so, please visit Axsome Therapeutics, Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights. 
Jun 29, 2022 03:23 pm ET
Axsome Therapeutics, Inc. Investors: Filing date July 12, 2022; Contact the Portnoy Law Firm to Recover Losses
The Portnoy Law Firm advises Axsome Therapeutics, Inc. (“Axsome” or the “Company”) (NASDAQ: AXSM) investors that a class action filed on behalf of investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email:...
Jun 29, 2022 12:04 pm ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Axsome Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 12, 2022 - (NASDAQ: AXSM)
NEW YORK, June 29, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Axsome Therapeutics, Inc..
Jun 29, 2022 10:30 am ET
Thinking about buying stock in Marathon Oil, Sundial Growers, SoFi Technologies, Intel Corp, or Axsome Therapeutics?
NEW YORK, June 29, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MRO, SNDL, SOFI, INTC, and AXSM.
Jun 28, 2022 01:00 pm ET
DEADLINE ALERT for FHS, OSCR, UPST, AXSM: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jun 28, 2022 12:00 pm ET
AXSOME THERAPEUTICS, INC. (NASDAQ: AXSM) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit A
Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the...
Jun 28, 2022 07:00 am ET
Axsome Therapeutics Hosts Sunosi® Investor Update Virtual Event Today with Key Opinion Leaders
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, is hosting a virtual event today at 9:00 AM EDT to provide investors an...
Jun 28, 2022 05:45 am ET
AXSM ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of July 12, 2022 in the Class Action Filed on Behalf of Axsome Therapeutics, Inc. Shareholders
NEW YORK , June 28, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM) alleging that the Company violated federal securities laws.
Jun 27, 2022 07:56 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Axsome Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - AXSM
NEW YORK, June 27, 2022 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Axsome Therapeutics, Inc. ("Axsome" or the "Company") (NASDAQ: AXSM) and certain of its officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 22-cv-03925, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Axsome securities between December 30, 2019 and April 22, 2022, both dates inclusive (the "Class Period"), seeking to recover damage
Jun 27, 2022 04:15 pm ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Axsome Investors of a Lead Plaintiff Deadline of July 12, 2022
NEW YORK, June 27, 2022 /PRNewswire/ -- Attention Axsome Therapeutics, Inc. ("Axsome") (NASDAQ: AXSM) shareholders:
Jun 27, 2022 11:45 am ET
DEADLINE ALERT for FHS, OSCR, UPST, and AXSM: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Jun 27, 2022 08:30 am ET
Thinking about buying stock in Epizyme, Acutus Medical, Agile Therapeutics, Axsome Therapeutics, or Evofem Biosciences?
NEW YORK, June 27, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EPZM, AFIB, AGRX, AXSM, and EVFM.
Jun 25, 2022 12:18 pm ET
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important July 12 Deadline in Securities Class Action – AXSM
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Axsome Therapeutics, Inc. (NASDAQ: AXSM) between December 30, 2019 and April 22, 2022, inclusive (the “Class Period”), of the important July 12, 2022...
Jun 24, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Axsome, Pegasystems, Humbl, and Okta and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM), Pegasystems, Inc. (NASDAQ: PEGA),...
Jun 24, 2022 07:41 pm ET
AXSOME THERAPEUTICS, INC. (NASDAQ: AXSM) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit A
Did you lose money on investments in Axsome Therapeutics? If so, please visit Axsome Therapeutics, Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
Jun 24, 2022 05:45 am ET
AXSM SHAREHOLDER ALERT: Jakubowitz Law Reminds Axsome Shareholders of a Lead Plaintiff Deadline of July 12, 2022
NEW YORK, June 24, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM).
Jun 23, 2022 02:11 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Axsome Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – AXSM
Pomerantz LLP announces that a class action lawsuit has been filed against Axsome Therapeutics, Inc. (“Axsome” or the “Company”) (NASDAQ: AXSM) and certain of its officers. The class action, filed in the United States District Court for the...
Jun 23, 2022 05:45 am ET
AXSM LAWSUIT ALERT: Levi & Korsinsky Notifies Axsome Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, June 23, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Axsome Therapeutics, Inc. ("Axsome" or the "Company") (NASDAQ: AXSM) of a class action securities lawsuit.
Jun 22, 2022 11:45 pm ET
AXSM Investors Have Opportunity to Lead Axsome Therapeutics, Inc. Securities Fraud Lawsuit
Shareholders with $500,000 losses or more are encouraged to contact the firm. 
Jun 22, 2022 12:30 pm ET
AXSOME THERAPEUTICS, INC. (NASDAQ: AXSM) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit A
Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the...
Jun 22, 2022 07:00 am ET
Axsome Therapeutics to Host Sunosi® Investor Update Virtual Event
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that it will host a virtual event on Tuesday, June 28,...
Jun 22, 2022 05:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Axsome Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 12, 2022 - (NASDAQ: AXSM)
NEW YORK, June 22, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Axsome Therapeutics, Inc..
Jun 21, 2022 11:45 am ET
DEADLINE ALERT for FHS, OSCR, UPST, and AXSM: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Jun 21, 2022 05:45 am ET
AXSM ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of July 12, 2022 in the Class Action Filed on Behalf of Axsome Therapeutics, Inc. Shareholders
NEW YORK, June 21, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM) alleging that the Company violated federal securities laws.
Jun 20, 2022 05:45 am ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Axsome Investors of a Lead Plaintiff Deadline of July 12, 2022
NEW YORK, June 20, 2022 /PRNewswire/ -- Attention Axsome Therapeutics, Inc. ("Axsome") (NASDAQ: AXSM) shareholders:
Jun 20, 2022 01:18 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Axsome Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - AXSM
NEW YORK, June 20, 2022 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Axsome Therapeutics, Inc. ("Axsome" or the "Company") (NASDAQ: AXSM) and certain of its officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 22-cv-03925, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Axsome securities between December 30, 2019 and April 22, 2022, both dates inclusive (the "Class Period"), seeking to recover damage
Jun 19, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against First High-School, Upstart, Oscar Health, and Axsome and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of First High-School Education Group Co. Ltd. (NYSE: FHS), Upstart Holdings, Inc....
Jun 19, 2022 07:00 pm ET
GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – AXSM
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Axsome Therapeutics, Inc. (NASDAQ: AXSM) between December 30, 2019 and April 22, 2022, inclusive (the “Class Period”), of the important July 12, 2022...
Jun 17, 2022 05:45 am ET
AXSM SHAREHOLDER ALERT: Jakubowitz Law Reminds Axsome Shareholders of a Lead Plaintiff Deadline of July 12, 2022
NEW YORK, June 17, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM).
Jun 16, 2022 11:00 am ET
DEADLINE ALERT for FHS, OSCR, UPST, AXSM: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jun 16, 2022 05:45 am ET
AXSM LAWSUIT ALERT: Levi & Korsinsky Notifies Axsome Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, June 16, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Axsome Therapeutics, Inc. ("Axsome" or the "Company") (NASDAQ: AXSM) of a class action securities lawsuit.
Jun 15, 2022 12:30 pm ET
AXSOME THERAPEUTICS, INC. (NASDAQ: AXSM) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit A
Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the...
Jun 15, 2022 11:00 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Axsome Therapeutics, Inc. (AXSM)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming July 12, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Axsome Therapeutics, Inc. (“Axsome” or...
Jun 15, 2022 05:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Axsome Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 12, 2022 - (NASDAQ: AXSM)
NEW YORK, June 15, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Axsome Therapeutics, Inc..
Jun 14, 2022 11:45 am ET
DEADLINE ALERT for FHS, OSCR, UPST, and AXSM: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Jun 14, 2022 05:45 am ET
AXSM ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of July 12, 2022 in the Class Action Filed on Behalf of Axsome Therapeutics, Inc. Shareholders
NEW YORK, June 14, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM) alleging that the Company violated federal securities laws.
Jun 13, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against First High-School, Upstart, Oscar, and Axsome and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of First High-School Education Group Co., Ltd. (NYSE: FHS), Upstart Holdings, Inc....
Jun 13, 2022 06:38 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Axsome Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – AXSM
Pomerantz LLP announces that a class action lawsuit has been filed against Axsome Therapeutics, Inc. (“Axsome” or the “Company”) (NASDAQ: AXSM) and certain of its officers. The class action, filed in the United States District Court for the...
Jun 13, 2022 08:00 am ET
Axsome Therapeutics, Inc. Investors: Contact the Portnoy Law Firm to Recover Losses
The Portnoy Law Firm advises Axsome Therapeutics, Inc. (“Axsome” or the “Company”) (NASDAQ: AXSM) investors that a class action filed on behalf of investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email:...
Jun 13, 2022 05:49 am ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Axsome Investors of a Lead Plaintiff Deadline of July 12, 2022
NEW YORK, June 13, 2022 /PRNewswire/ -- Attention Axsome Therapeutics, Inc. ("Axsome") (NASDAQ: AXSM) shareholders:
Jun 12, 2022 03:15 pm ET
ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – AXSM
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Axsome Therapeutics, Inc. (NASDAQ: AXSM) between December 30, 2019 and April 22, 2022, inclusive (the “Class Period”), of the important July 12, 2022...
Jun 10, 2022 05:45 am ET
AXSM SHAREHOLDER ALERT: Jakubowitz Law Reminds Axsome Shareholders of a Lead Plaintiff Deadline of July 12, 2022
NEW YORK, June 10, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM).
Jun 09, 2022 01:00 pm ET
DEADLINE ALERT for FHS, OSCR, UPST, AXSM: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jun 09, 2022 05:45 am ET
AXSM LAWSUIT ALERT: Levi & Korsinsky Notifies Axsome Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, June 9, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Axsome Therapeutics, Inc. ("Axsome" or the "Company") (NASDAQ: AXSM) of a class action securities lawsuit.
Jun 08, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Upstart, Oscar, Axsome, and Humbl and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Upstart Holdings, Inc. (NASDAQ: UPST), Oscar Health, Inc. (NYSE: OSCR), Axsome...
Jun 08, 2022 08:45 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Axsome Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - AXSM
NEW YORK, June 8, 2022 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Axsome Therapeutics, Inc. ("Axsome" or the "Company") (NASDAQ: AXSM) and certain of its officers.  The class action, filed in the United States District Court for the Southern District of New York, and docketed under 22-cv-03925, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Axsome securities between December 30, 2019 and April 22, 2022, both dates inclusive (the "Class Period"), seeking to recover damage
Jun 08, 2022 12:30 pm ET
AXSOME THERAPEUTICS, INC. (NASDAQ: AXSM) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit A
Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the...
Jun 08, 2022 05:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Axsome Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 12, 2022 - (NASDAQ: AXSM)
NEW YORK, June 8, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Axsome Therapeutics, Inc..
Jun 07, 2022 01:00 pm ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Axsome Therapeutics, Inc. (AXSM)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming July 12, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Axsome Therapeutics, Inc. (“Axsome” or...
Jun 07, 2022 11:45 am ET
DEADLINE ALERT for FHS, OSCR, UPST, and AXSM: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jun 07, 2022 05:45 am ET
AXSM ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of July 12, 2022 in the Class Action Filed on Behalf of Axsome Therapeutics, Inc. Shareholders
NEW YORK, June 7, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM) alleging that the Company violated federal securities laws.
Jun 06, 2022 11:00 am ET
AXSM Investors Have Opportunity to Lead Axsome Therapeutics, Inc. Securities Fraud Lawsuit
Shareholders with $500,000 losses or more are encouraged to contact the firm. 
Jun 06, 2022 07:00 am ET
Axsome Therapeutics Announces Results of the SUPPORT Survey of Patients with Major Depressive Disorder Presented at the American Society of Clinical Psychopharmacology Association (ASCP) 2022 Annual M
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced the results of the SUPPORT (Studying the Impact of Patient...
Jun 05, 2022 02:43 pm ET
ROSEN, LEADING INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – AXSM
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Axsome Therapeutics, Inc. (NASDAQ: AXSM) between December 30, 2019 and April 22, 2022, inclusive (the “Class Period”), of the important July 12, 2022...
Jun 04, 2022 08:16 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Axsome Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – AXSM
Pomerantz LLP announces that a class action lawsuit has been filed against Axsome Therapeutics, Inc. (“Axsome” or the “Company”) (NASDAQ: AXSM) and certain of its officers.   The class action, filed in the United States District Court for the...
Jun 03, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Oscar Health, Axsome, Humbl, and Okta and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Oscar Health, Inc. (NYSE: OSCR), Axsome Therapeutics, Inc. (NASDAQ: AXSM),...
Jun 03, 2022 12:00 pm ET
AXSM Investors Have Opportunity to Lead Axsome Therapeutics, Inc. Securities Fraud Lawsuit
Shareholders with $500,000 losses or more are encouraged to contact the firm. 
Jun 03, 2022 11:45 am ET
DEADLINE ALERT for FHS, OSCR, UPST, and AXSM: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Jun 03, 2022 05:45 am ET
AXSM SHAREHOLDER ALERT: Jakubowitz Law Reminds Axsome Shareholders of a Lead Plaintiff Deadline of July 12, 2022
NEW YORK, June 3, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM).
Jun 02, 2022 03:29 pm ET
Axsome Therapeutics, Inc. Investors: Contact the Portnoy Law Firm to Recover Losses
The Portnoy Law Firm advises Axsome Therapeutics, Inc. (“Axsome” or the “Company”) (NASDAQ: AXSM) investors that a class action filed on behalf of investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email:...
Jun 02, 2022 01:41 pm ET
AXSM LAWSUIT ALERT: Levi & Korsinsky Notifies Axsome Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, June 2, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Axsome Therapeutics, Inc. ("Axsome" or the "Company") (NASDAQ: AXSM) of a class action securities lawsuit.
Jun 02, 2022 11:00 am ET
DEADLINE ALERT for FHS, OSCR, UPST, AXSM: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jun 02, 2022 10:58 am ET
Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Axsome Therapeutics, Inc. (AXSM) Investors of Class Action and Encourages Shareholders to Contact the Firm
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Axsome Therapeutics, Inc. (“Axsome” or the “Company) (NASDAQ: AXSM) and certain of its officers, on behalf of...
Jun 02, 2022 07:00 am ET
Axsome Therapeutics Presents New Data from the GEMINI Trial Demonstrating Efficacy of AXS-05 on Anhedonia in Patients with Major Depressive Disorder
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that treatment with AXS-05 (dextromethorphan-bupropion)...
Jun 01, 2022 06:41 pm ET
Axsome Therapeutics, Inc. Investor News: Robbins LLP is Investigating Axsome Therapeutics, Inc. (AXSM) on Behalf of Shareholders
Shareholder rights law firm Robbins LLP is investigating Axsome Therapeutics, Inc. (NASDAQ: AXSM) and its officers and directors to determine whether they breached their fiduciary duties and violated securities laws in connection with its New Drug Application for AXS-07 for the acute treatment of migraine. Axsome is a biopharma
Jun 01, 2022 04:09 pm ET
AXSOME THERAPEUTICS, INC. (NASDAQ: AXSM) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit A
Did you lose money on investments in Axsome Therapeutics?  If so, please visit Axsome Therapeutics, Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.                                                                                     
Jun 01, 2022 07:00 am ET
Axsome Therapeutics Announces Late-Breaking Presentations of Positive Results of the EVOLVE Trial of AXS-05 in Major Depressive Disorder After Prior Treatment Failures at the American Society of Clini
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced positive results from the long-term, open-label EVOLVE...
Jun 01, 2022 05:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Axsome Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 12, 2022 - (NASDAQ: AXSM)
NEW YORK, June 1, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Axsome Therapeutics, Inc..
Jun 01, 2022 12:30 am ET
AXSOME THERAPEUTICS, INC. (NASDAQ: AXSM) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit A
Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the...
May 31, 2022 03:15 pm ET
ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AXSM
NEW YORK, May 31, 2022 /PRNewswire/ -- WHY: New York, N.Y., May 31, 2022. Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Axsome Therapeutics, Inc. (NASDAQ: AXSM) between December 30, 2019 and April 22, 2022, inclusive (the "Class Period"), of the important July 12, 2022 lead plaintiff deadline.
May 31, 2022 01:40 pm ET
AXSM ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of July 12, 2022 in the Class Action Filed on Behalf of Axsome Therapeutics, Inc. Shareholders
NEW YORK, May 31, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM) alleging that the Company violated federal securities laws.
May 31, 2022 11:00 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Axsome Therapeutics, Inc. (AXSM)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming July 12, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Axsome Therapeutics, Inc. (“Axsome” or...
May 31, 2022 07:39 am ET
Axsome Therapeutics Announces Publication of Pivotal GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder in The Journal of Clinical Psychiatry
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced the publication on May 30, 2022 of the results from the...
May 31, 2022 07:00 am ET
Axsome Therapeutics Announces Publication of Pivotal GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder in The Journal of Clinical Psychiatry
AXS-05 (dextromethorphan-bupropion) demonstrated rapid, substantial, and statistically significant antidepressant efficacy compared to placebo starting 1 week after treatment
May 30, 2022 08:00 pm ET
AXSM INVESTOR NEWS: ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Axsome Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Axsome Therapeutics, Inc. (NASDAQ: AXSM) between December 30, 2019 and April 22, 2022, inclusive (the “Class Period”), of the important July 12, 2022...
May 30, 2022 05:07 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Axsome Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - AXSM
NEW YORK , May 30, 2022 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Axsome Therapeutics, Inc. ("Axsome" or the "Company") (NASDAQ: AXSM) and certain of its officers.  The class action, filed in the United States District Court for the Southern District of New York, and docketed under 22-cv-03925, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Axsome securities between December 30, 2019 and April 22, 2022, both dates inclusive (the "Class Period"), seeking to recover damag
May 29, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Axsome, Humbl, Okta, and CareDx and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM), Humbl, Inc. (OTCMKTS: HMBL), Okta,...
May 27, 2022 05:45 am ET
AXSM SHAREHOLDER ALERT: Jakubowitz Law Reminds Axsome Shareholders of a Lead Plaintiff Deadline of July 12, 2022
NEW YORK, May 27, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM).
May 26, 2022 01:00 pm ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Axsome Therapeutics, Inc. (AXSM)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming July 12, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Axsome Therapeutics, Inc. (“Axsome” or the “Company”) (NASDAQ:
May 26, 2022 11:45 am ET
DEADLINE ALERT for FHS, OSCR, UPST, and AXSM: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
May 26, 2022 09:25 am ET
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action – AXSM
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Axsome Therapeutics, Inc. (NASDAQ: AXSM) between December 30, 2019 and April 22, 2022, inclusive (the “Class Period”), of the important July 12, 2022...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.